Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Immune Regulation Strategies Beyond Immunosuppression: IL-2, Metabolic Reprogramming, and T-Cell Engagers

Description

The talk reviewed strategies to restore immune tolerance beyond conventional immunosuppression in autoimmune disease, focusing on regulatory T cells and three main approaches: IL-2-based therapy, metabolic reprogramming, and T-cell engagers. Regulatory T cells normally suppress excessive immune responses but are insufficient in autoimmunity. IL-2 is a key cytokine for their survival and function, and because regulatory T cells express the high-affinity trimeric IL-2 receptor, low-dose IL-2 can preferentially expand them, while high-dose IL-2 strongly activates effector cells and causes toxicity. The speaker discussed newer IL-2 formulations such as pegylated IL-2, muteins, fusion proteins, and antibody-based targeting to improve selectivity. Clinical data were highlighted in dermatology, including atopic dermatitis, alopecia areata, and vitiligo, with reported improvements and manageable transient side effects. The talk also described gluconolactone as a metabolic modulator identified through metabolomics in SLE; by shifting immune-cell metabolism, it appears to favor regulatory cells over effector cells and showed rapid effects in preclinical models and patient cases. Finally, T-cell engagers were introduced as part of an immune-reset concept, binding T cells and specific antigens to redirect immune activity, alongside CAR-T approaches. Overall, the lecture emphasized emerging ways to rebalance immunity and potentially induce lasting remission.

View more

Conclusions

Low-dose IL-2 appears to selectively bolster regulatory T cells and restore immune tolerance in autoimmune skin disease without the toxicity seen with high-dose IL-2.
Pegylated or engineered IL-2 formulations can preserve the tolerance-promoting benefits of IL-2 while improving selectivity and reducing off-target activation.
Clinical data presented suggest meaningful efficacy of REZPEG in atopic dermatitis, with clear dose-dependent EASI improvement and an acceptable safety profile.
In alopecia areata, REZPEG showed clinically relevant SALT score reductions and produced notable hair regrowth in some individual patients.
Vitiligo may improve when regulatory T-cell function is enhanced, and low-dose IL-2 showed repigmentation signals in proof-of-concept studies.
Adding narrowband UVB to low-dose IL-2 may further accelerate repigmentation in vitiligo, while mechanistic studies indicate increased Treg activity and improved Treg-to-CD8 balance.
Immune metabolic reprogramming with gluconolactone can shift immune cells toward a regulatory state and rapidly reduce lupus-related skin inflammation.
The metabolic approach may work by exploiting pathway dysregulation so that Tregs are favored while effector cells are relatively disadvantaged.
T-cell engager strategies are being explored as a way to deplete pathogenic immune populations or achieve a more complete immune reset.
Across the presentation, the central conclusion is that immune tolerance in autoimmunity may be restored by reinforcing regulation, reprogramming metabolism, or resetting the immune repertoire rather than relying only on broad immunosuppression.

Kolios and Behnend, 2017.
Gao R et al., Front Immunol, 2022.
Karakus U et al., Sci Transl Med, 2020.
adapted from Kios AGA et al., Nat Rev Rheumatol, 2021.
10.1126/scitranslmed.adp4447#10.1126/scitranslmed.adp4447
Kuter DJ et al., Blood Rev, 2026.
Baeuerle PA et al., J Exp Med, 2026.
Rolin C et al., Cell Mol Immunol, 2024.